Rostislav Raykov, CEO
Mr. Raykov has served as a director of Fennec Pharma and Chief Executive Officer since July 2009. Mr. Raykov is a General Partner at DCML, a private investment partnership. Prior to DCML, Mr. Raykov was a co-founder and portfolio manager for Alchem Investment Partners, an event driven hedge fund. Mr. Raykov also worked as a portfolio manager for Purchase Associates, an event driven hedge fund owned by John Levin & Co. He began his career as a financial analyst in the natural resources group at Bear Stearns. Mr. Raykov graduated from University of North Carolina at Chapel Hill, where he earned a Bachelor of Science degree in business administration.
Robert Andrade, CFO
Robert Andrade joined Fennec Pharma in November 2015 as Chief Financial Officer. Mr. Andrade was previously a director and Chief Financial Officer of Fennec Pharma from September 2009 until August 2013. Prior to Fennec, Mr. Andrade has over 17 years of financial and capital markets experience that includes numerous financings and merger and acquisitions transactions. In addition to Mr. Andrade’s tenure with Fennec Pharmaceuticals, his financial experience includes senior invesment positions at Magnetar Capital, Millennium Partners and Caxton Associates.
Mark Gowland joined Fennec Pharma in November 2015 as Controller. Mr. Gowland is a Certified Public Accountant and Certified Global Management Accountant. Mr. Gowland has worked for Cisco in project management, Controller for DNA Group and CFO for Gorbec Pharmaceuticals, Inc.
Anne McKay joined Fennec Pharma in May 2010 and is directing the regulatory and quality aspects of Fennec Pharma projects. Anne has over 30 years of experience in the regulatory affairs and quality assurance areas of the pharmaceutical industry. Currently she manages her own consulting company. Other prior positions were Vice President of Regulatory Affairs at Biolex Therapeutics, Senior Director of Regulatory Affairs at RTI Health Solutions, Principal, BWA Consulting LLC, and Executive VP of Triangle Pharmaceuticals. At Triangle she was an Officer of the publically-traded company and a very active member of the acquisition team when Triangle was purchased by Gilead Sciences for $500M in January 2003. Prior to Triangle, Anne served as Director, Regulatory Affairs for Medco Research and spent 15 years at Burroughs Wellcome Co. where she held many positions of increasing responsibility, ending as Director, Regulatory Affairs, North America. Anne received her BS in Animal Science from Michigan State University.
Lei Fang joined Fennec Pharma in May 2010 and is responsible for all biostatistics aspects of Fennec Pharma projects. Lei is currently President of Pharstat Inc., a drug development services company providing biostatistics, clinical pharmacokinetics, and statistical programming services to pharmaceutical and biotechnology companies. Lei has over 20 years of pharmaceuticals industry experiences in clinical research and development and statistics. He has been employed as senior statistician at Trimeris, Inc., Triangle Pharmaceuticals, Inc., Quintiles, and GlaxoWellcome. Lei has a thorough knowledge of clinical trial design and implementation and extensive experience in IND and NDA preparations. He is an excellent SAS programmer and well versed in statistical methods, database design and development. Lei received his MS in Biostatistics from the Medical University of South Carolina, and his BS in Electrical Engineering from Zhejiang University, China.